Inhaled Furosemide for Transient Tachypnea of Newborn

Makassed General Hospital

Status: Completed

Conditions: Respiratory Morbidity

Treatments: Other: Furosemide; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04397991

18122018

Details and patient eligibility

About

This is a randomized double blind clinical trial in which newborns with suspected Transient tachypnea of the newborn (TTN) will receive either furosemide or normal saline by nebulizer every 6 hours for 24 hours.

Enrollment: 64 patients

Sex: All

Ages: 1 to 1 day old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Neonates with 34+0-39+0 gestational age
• on the first day of life
• with the clinical diagnosis of Transient Tachypnoea
• need for CPAP >6 hours to obtain the oxygen saturation >92%

Exclusion criteria

• Systemic infection
• Intubation and mechanical ventilation before Inclusion in the trail
• Malformation and any other disease with disturb of respiratory system

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

64 participants in 2 patient groups, including a placebo group

Furosemide

Experimental group

Description:

Patients will receive nebulised furosemide

Treatment:

Other: Furosemide

Placebo

Placebo Comparator group

Description:

Patients will receive nebulised 0.9% saline

Treatment:

Other: Placebo